Valuation dashboard for Baxter International Inc. (BAX) with P/E N/A, P/B 1.96, EV/EBITDA 23.29 and dividend yield 0.17%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution.
Analysis Summary
Baxter International Inc. reported revenue of $11.24B in the most recent fiscal year, growing at a 5-year CAGR of -0.7%.
Trailing-twelve-month margins: gross margin 30.1%, operating margin -2.4%, net margin -9.3%.
At the current price of $23.53, BAX has negative trailing earnings (P/E not meaningful) and an ROE of -15.61%. Market capitalisation stands at $12.2B, placing it among large-cap names.
Balance sheet quality for BAX: current ratio of 2.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.96 |
| EV / EBITDA | 23.29 |
| Dividend Yield | 0.17% |
Valuation Models
| DCF Fair Value | $-5.19 |
| vs Current Price | -122.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BAX | Baxter International Inc. | $12.2B | 1.96 | -15.6% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.2B | 29.72 | -56.6% | |
| MASI | Masimo Corporation | $9.4B | 124.97 | 11.91 | 9.1% |
| DVA | DaVita Inc. | $12.1B | |||
| ATR | AptarGroup, Inc. | $8.0B | |||
| QGEN | Qiagen N.V. | $8.8B | 21.78 | 2.61 | |
| BIO | Bio-Rad Laboratories, Inc. | $10.2B | 45.63 | 1.42 | 3.2% |
| AVTR | Avantor, Inc. | $10.6B | 1.90 | -9.5% |
Price
| Price | $23.53 |
| Market Cap | $12.2B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | -15.61% |
| Return on Invested Capital | -1.79% |
| Return on Assets | -4.77% |
| Gross Margin | 30.08% |
| Operating Margin | -2.39% |
| Net Margin | -9.27% |
Related companies: ATR · AVTR · BIO · DVA · HIMS · MASI · MDGL
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BAX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks